TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
Want to see TLSI full AI Analyst Report?
Earnings Data
Report Date
Aug 19, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.15Last Year’s EPS
-0.27Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized a major clinical and economic validation of PEDD (landmark real-world study, strong pipeline, meaningful early results in multiple new indications) and a deliberate commercial build intended to capture a large addressable market. Near-term financials were impacted by the deliberate salesforce expansion (temporary revenue disruption, higher operating losses) and a regulatory delay for TriNav Advance that defers some expected second-half revenue. Management positions the investments as strategic and funded by a solid cash balance, with expectations of sustained ramp and commercial momentum through the remainder of 2026 and beyond.Company Guidance
Landmark Real-World Evidence Publication Validating PEDD
Published largest real-world evidence study of PEDD (603 PEDD patients matched to >16,200 non-PEDD patients from a 300M-patient claims database covering 96% of US payers; cohort: 515 TACE, 88 TARE). Key outcomes: post-procedure fatigue 20.9% vs 26.4% (absolute -5.5pp), lymphopenia 0.6% vs 5.2% (absolute -4.6pp, ~88% relative reduction), TACE 30-day inpatient admissions 8% vs 20.5% (absolute -12.5pp, >50% reduction), PEDD delivered ~48% more doxorubicin per procedure. Per-patient downstream cost avoidance ≈ $7.7k (≈ $3.1k from fewer inpatient stays + $4.6k from fewer complications).
Strong Clinical Pipeline and Growing Evidence Base
10 active studies across 24 sites (>400 TriNav-treated patients); two new prospective trials beginning (PRESSURE at Stanford randomized TriNav vs TARE; PREDICT at MD Anderson for hypovascular tumors). Two completed investigator-initiated trials (TETHER at MGH, TRI-FI 90 at MD Anderson) targeting submission this quarter, plus two large retrospective TARE-in-HCC studies initiated.
Expansion into Multiple High-Potential Indications
Momentum in new applications: uterine artery embolization (median dominant fibroid volume reduction 97.5% vs historical ~50%; 100% technical success, no device-related complications), PROTECT thyroid registry (100% technical/clinical success; 73% thyroid size reduction; 71% normalization rate), genicular artery embolization pilot moving to formal trial. Combined US addressable market across liver and new applications ≈ $2.5 billion.
Commercial Organization Build and Leadership Added
Commercial footprint materially expanded (sales organization more than doubled; added senior VP of Sales & Commercial Ops Chris Sowd). 60% of territories performed in line with expectations during transition, organization largely in place by May; expected rep ramp 6–9 months supporting multi‑year growth.
Improved Gross Margin and Solid Cash Position
Q1 gross margin 86% vs 84% year-ago (+2 percentage points) driven by lower average unit cost and manufacturing improvements. Cash and cash equivalents $56.6M as of 03/31/2026, stated as sufficient to fund strategic growth plan.
TLSI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TLSI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $4.56 | $2.67 | -41.45% |
Mar 05, 2026 | $4.77 | $4.46 | -6.39% |
Nov 13, 2025 | $4.39 | $4.56 | +3.87% |
Aug 12, 2025 | $3.65 | $3.95 | +8.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does TriSalus Life Sciences (TLSI) report earnings?
TriSalus Life Sciences (TLSI) is schdueled to report earning on Aug 19, 2026, Before Open (Confirmed).
What is TriSalus Life Sciences (TLSI) earnings time?
TriSalus Life Sciences (TLSI) earnings time is at Aug 19, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TLSI EPS forecast?
TLSI EPS forecast for the fiscal quarter 2026 (Q2) is -0.15.